<?xml version="1.0" encoding="UTF-8"?>
<gtr:projectOverview xmlns:gtr="http://gtr.ukri.org/api"><gtr:projectComposition><gtr:collaborations><gtr:collaborator url="http://gtr.ukri.org:80/organisation/20E66A18-4A43-4DD5-BA98-5320F6EC9269"><gtr:id>20E66A18-4A43-4DD5-BA98-5320F6EC9269</gtr:id><gtr:name>GlaxoSmithKline (GSK)</gtr:name></gtr:collaborator></gtr:collaborations><gtr:leadResearchOrganisation url="http://gtr.ukri.org:80/organisation/3EAE04CA-9D62-4483-B9C4-F91AD9F4C5A9"><gtr:id>3EAE04CA-9D62-4483-B9C4-F91AD9F4C5A9</gtr:id><gtr:name>University of Oxford</gtr:name><gtr:department>Oxford Chemistry</gtr:department><gtr:address><gtr:line1>University Chest</gtr:line1><gtr:line2>Wellington Square</gtr:line2><gtr:line4>Oxford</gtr:line4><gtr:postCode>OX1 2JD</gtr:postCode><gtr:region>South East</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:typeInd>RO</gtr:typeInd></gtr:leadResearchOrganisation><gtr:organisationRoles><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/3EAE04CA-9D62-4483-B9C4-F91AD9F4C5A9"><gtr:id>3EAE04CA-9D62-4483-B9C4-F91AD9F4C5A9</gtr:id><gtr:name>University of Oxford</gtr:name><gtr:address><gtr:line1>University Chest</gtr:line1><gtr:line2>Wellington Square</gtr:line2><gtr:line4>Oxford</gtr:line4><gtr:postCode>OX1 2JD</gtr:postCode><gtr:region>South East</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>LEAD_RO</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/20E66A18-4A43-4DD5-BA98-5320F6EC9269"><gtr:id>20E66A18-4A43-4DD5-BA98-5320F6EC9269</gtr:id><gtr:name>GlaxoSmithKline (GSK)</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/DF0020F8-9212-4670-ADC0-CBDFF5B93548"><gtr:id>DF0020F8-9212-4670-ADC0-CBDFF5B93548</gtr:id><gtr:name>GlaxoSmithKline</gtr:name><gtr:address><gtr:line1>Stockley Park West</gtr:line1><gtr:line4>Uxbridge</gtr:line4><gtr:postCode>UB11 1BT</gtr:postCode><gtr:region>London</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>PROJECT_PARTNER</gtr:name></gtr:role></gtr:roles></gtr:organisationRole></gtr:organisationRoles><gtr:personRoles><gtr:personRole url="http://gtr.ukri.org:80/person/43D3A53C-97DD-4BD8-93CB-4A762D8471A9"><gtr:id>43D3A53C-97DD-4BD8-93CB-4A762D8471A9</gtr:id><gtr:firstName>Michael</gtr:firstName><gtr:surname>Willis</gtr:surname><gtr:roles><gtr:role><gtr:name>PRINCIPAL_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole></gtr:personRoles><gtr:project url="http://gtr.ukri.org:80/projects?ref=EP%2FE020232%2F1"><gtr:id>C72FC4E7-84D0-4920-8927-15E25D198D9C</gtr:id><gtr:title>Cascade C-N, C-O and C-S Bond Formation: Copper and Palladium Catalysed Synthesis of Heterocycle Arrays</gtr:title><gtr:status>Closed</gtr:status><gtr:grantCategory>Research Grant</gtr:grantCategory><gtr:grantReference>EP/E020232/1</gtr:grantReference><gtr:abstractText>The chemistry in this proposal involves the development of a series of cascade processes based on combinations of C-N, C-O, C-S and C-C coupling reactions, mediated by copper and palladium based catalysts, to deliver a variety of functionalised heterocyclic products. Significant variation of the heterocyclic core and the nature and position of the substituents will be possible employing what is essentially a single strategy. Although the individual reactions used to construct these cascades are well established, it is the ability to combine them in productive processes that will allow valuable drug-like molecules to be produced. Cascades of C-X bond forming reactions offer great potential for heterocycle synthesis as they the introduction of the functional groups and heteroatom combinations frequently encountered in drug-like molecules. Cascade sequences involving up to four bond forming processes will be used to prepare complex, drug-like molecules in a single step. A significant aspect of the chemistry involves demonstrating that it can be applied to array synthesis.</gtr:abstractText><gtr:fund><gtr:end>2009-09-30</gtr:end><gtr:funder url="http://gtr.ukri.org:80/organisation/798CB33D-C79E-4578-83F2-72606407192C"><gtr:id>798CB33D-C79E-4578-83F2-72606407192C</gtr:id><gtr:name>EPSRC</gtr:name></gtr:funder><gtr:start>2007-06-01</gtr:start><gtr:type>INCOME_ACTUAL</gtr:type><gtr:valuePounds>148549</gtr:valuePounds></gtr:fund><gtr:output><gtr:artisticAndCreativeProductOutputs/><gtr:collaborationOutputs><gtr:collaborationOutput><gtr:collaboratingOrganisation>GlaxoSmithKline (GSK)</gtr:collaboratingOrganisation><gtr:country>Global</gtr:country><gtr:description>GlaxoSmithKline R &amp;amp; D Ltd</gtr:description><gtr:id>994205B0-AE9D-4A6B-92E5-C287A5A19825</gtr:id><gtr:outcomeId>b9c9ad56b9c9ad6a-1</gtr:outcomeId><gtr:sector>Private</gtr:sector><gtr:start>2007-01-01</gtr:start></gtr:collaborationOutput></gtr:collaborationOutputs><gtr:disseminationOutputs/><gtr:exploitationOutputs/><gtr:furtherFundingOutputs/><gtr:impactSummaryOutputs/><gtr:intellectualPropertyOutputs/><gtr:otherResearchOutputs/><gtr:policyInfluenceOutputs/><gtr:productOutputs/><gtr:researchDatabaseAndModelOutputs/><gtr:researchMaterialOutputs/><gtr:softwareAndTechnicalProductOutputs/><gtr:spinOutOutputs/></gtr:output><gtr:publications><gtr:publication><gtr:id>478A4357-F062-47F6-9670-36153798B299</gtr:id><gtr:title>Palladium-catalyzed aminosulfonylation of aryl halides.</gtr:title><gtr:parentPublicationTitle>Journal of the American Chemical Society</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/aa25236f89b29d4fec2525abf6d025be"><gtr:id>aa25236f89b29d4fec2525abf6d025be</gtr:id><gtr:otherNames>Nguyen B</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>0002-7863</gtr:issn><gtr:outcomeId>545cd66ad26527.46861316</gtr:outcomeId></gtr:publication></gtr:publications><gtr:identifiers><gtr:identifier type="RCUK">EP/E020232/1</gtr:identifier></gtr:identifiers><gtr:healthCategories/><gtr:researchActivities/><gtr:researchSubjects><gtr:researchSubject><gtr:id>60EBB420-734E-4DB5-B0F2-65A1115A27F8</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>Chemical synthesis</gtr:text></gtr:researchSubject></gtr:researchSubjects><gtr:researchTopics><gtr:researchTopic><gtr:id>454398F2-57A6-4959-8845-0F248CF4D5C4</gtr:id><gtr:percentage>50</gtr:percentage><gtr:text>Chemical Synthetic Methodology</gtr:text></gtr:researchTopic><gtr:researchTopic><gtr:id>D59C2DC2-AD17-4980-92F3-677EB001B765</gtr:id><gtr:percentage>50</gtr:percentage><gtr:text>Combinatorial Chemistry</gtr:text></gtr:researchTopic></gtr:researchTopics><gtr:rcukProgrammes/></gtr:project></gtr:projectComposition></gtr:projectOverview>